XML 44 R25.htm IDEA: XBRL DOCUMENT
v3.26.1

Cost of Revenue and Operating Expenses | 12 Months Ended
--- | ---
Dec. 31, 2025
Cost of Revenue and Operating Expenses [Abstract] |
COST OF REVENUE AND OPERATING EXPENSES | NOTE 18 – COST OF REVENUE AND OPERATING EXPENSES For the years ended December 31, 2025 and 2024 cost of revenue consisted of as follows;
|  | Years ended |
|  | December 31, |
|  | 2025 |  |  | 2024 |
Test kits |  | $ | 147,288 |  |  | $ | 196,333 |
Labor |  |  | - |  |  |  | 122,775 |
|  | $ | 147,288 |  |  | $ | 319,108 |
For the years ended December 31, 2025 and 2024, operating expenses consisted of the following:
|  | Years ended |
|  | December 31, |
Sales and marketing |  | 2025 |  |  | 2024 |
Salaries and benefits |  | $ | 619,156 |  |  | $ | 1,082,404 |
Professional and consulting fees |  |  | 452,868 |  |  |  | 798,958 |
Office expenses |  |  | 2,838 |  |  |  | 37,689 |
Travel and entertainment |  |  | 34,416 |  |  |  | 85,174 |
Depreciation and amortization |  |  | 4,896 |  |  |  | 4,686 |
Marketing and advertising |  |  | 2,706,259 |  |  |  | 4,570,546 |
Other |  |  | 76 |  |  |  | 1,876 |
|  | $ | 3,820,509 |  |  | $ | 6,581,333 |
|  | Years ended |
|  | December 31, |
Research and development |  | 2025 |  |  | 2024 |
Salaries and benefits |  | $ | 1,386,410 |  |  | $ | 3,586,217 |
Professional fees |  |  | 122,716 |  |  |  | 701,078 |
Clinical study expenses |  |  | 2,174,000 |  |  |  | 217,711 |
Office expenses |  |  | 271,265 |  |  |  | 192,558 |
Travel and entertainment |  |  | 36,469 |  |  |  | 101,446 |
Depreciation and amortization |  |  | 566,117 |  |  |  | 637,861 |
Materials for clinical studies |  |  | 348,814 |  |  |  | 280,913 |
|  | $ | 4,905,791 |  |  | $ | 5,717,784 |
|  | Years ended |
|  | December 31, |
Research and development - related party |  | 2025 |  |  | 2024 |
Professional fees |  | $ | 45,611 |  |  | $ | 114,224 |
Office expenses |  |  | 9,164 |  |  |  | 7,025 |
|  | $ | 54,775 |  |  | $ | 121,249 |
|  | Years ended |
|  | December 31, |
General and administrative |  | 2025 |  |  | 2024 |
Salaries and benefits |  | $ | 1,277,434 |  |  | $ | 2,419,614 |
Employee stock option expense |  |  | 1,472,279 |  |  |  | (63,117 | )
Professional and consulting fees |  |  | 1,306,520 |  |  |  | 2,485,031 |
Office expenses |  |  | 579,006 |  |  |  | 1,137,888 |
Insurance |  |  | 260,981 |  |  |  | 536,546 |
Travel and entertainment |  |  | 95,219 |  |  |  | 80,517 |
Depreciation and amortization |  |  | 44,707 |  |  |  | 54,082 |
Materials for clinical studies |  |  | 71,389 |  |  |  | - |
|  | $ | 5,107,535 |  |  | $ | 6,650,561 |
|  | Years ended |
|  | December 31, |
|  | 2025 |  |  | 2024 |
Impairment loss of intangible asset |  | $ | 2,640,280 |  |  | $ | - |
|  | Years ended |
|  | December 31, |
Restructuring expense |  | 2025 |  |  | 2024 |
Salaries and benefits |  | $ | - |  |  | $ | 229,711 |
Impairment loss |  |  | - |  |  |  | 47,449 |
|  | $ | - |  |  | $ | 277,160 |

X
- Definition The entire disclosure for cost of revenue and operating expenses. + References No definition available. + Details
Name: | mynz_CostOfRevenueAndOperatingExpensesDisclosureTextBlock
Namespace Prefix: | mynz_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration